Analyst Price Target is $10.00
▲ +235.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genprex in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 235.57% upside from the last price of $2.98.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Genprex. This Buy consensus rating has held steady for over two years.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Read More